Kantar Health Blog

  • Stephanie Hawthorne
    Oncology Conference Insight: ASCO 2013 --- Although first-line combination chemotherapy with a platinum (carboplatin or cisplatin) plus a taxane (primarily paclitaxel) is very successful at producing high response rates in first-line advanced ovarian cancer patients, the vast majority (up to 70%1) of these patients still experience a recurrence. Based on this high unmet need to extend progression free survival (PFS) in these first-line patients, maintenance therapy in now utilized in some advanced ovarian cancer patients.
    Continue Reading > | Go comment! | Share
  • Biomarkers in Breast Cancer: More Than Just HER2

    by Stephanie Hawthorne | Apr 8, 2013
    Stephanie Hawthorne
    Oncology Conference Insight - AACR 2013 --- On Sunday at the American Association for Cancer Research (AACR) 2013 annual meeting, Jose Baselga presented new data from the Phase III EMILIA trial (Abstract LB-63) that suggested a relationship between tumor biomarkers and efficacy of Kadcyla® (TDM-1, ado-trastuzumab emtansine; Roche/Genentech). Kadcyla is a novel antibody-drug conjugate that comprises a potent microtubule polymerization inhibitor conjugated to the Herceptin® (trastuzumab; Roche / Genentech) monoclonal antibody via a highly stable linker.
    Continue Reading > | Go comment! | Share
  • The Demise of Chemotherapy in Front-Line mCRPC?

    by Neesha Suvarna | Feb 15, 2013
    Neesha Suvarna
    Oncology Conference Insight - ASCO GU 2013 --- The metastatic castrate-resistant prostate cancer (mCRPC) market appears to be on a trajectory toward a relinquishment to novel hormonal agents and a regression of chemotherapy and other targeted therapies to later lines. If Jevtana manages to supersede docetaxel, it may only be a marginal improvement in this field, with a swap of one taxane for another.
    Continue Reading > | Go comment! | Share
  • Stephanie Hawthorne
    Oncology Conference Insight - ASCO GI 2013 With recent news being so heavily centered on targeted agents, it seems as though people often forget about the value that chemotherapy has provided over the years and, more importantly, that there is still room for improvement in these older regimens to generate significantly better outcomes for patients. Celgene was looking to take advantage of this sentiment when the company acquired Abraxis BioScience and their leading drug candidate, Abraxane®, an injectable suspension of nanoparticle albumin bound (nab)-paclitaxel.
    Continue Reading > | Go comment! | Share
  • Neesha Suvarna
    Oncology Conference Insight - ASCO GI 2013 Will ramucirumab be able to show an additive benefit when combined with an active agent in a tumor type where Avastin failed to do so? This is a huge unanswered question for ramucirumab: is the mechanism of action different enough to surpass the activity of Avastin?
    Continue Reading > | Go comment! | Share